A Phase 1/2, Open-Label, Multicenter, Dose Escalation And Dose Expansion Study Of NKTR-262 In Combination With Bempegaldeslekin (NKTR-214) And In Combination With Bempegaldeslekin (NKTR-214) Plus Nivolumab In Patients With Locally Advanced Or Metastatic Solid Tumor Malignancies
MD Anderson Study Status
NKTR-262, bempegaldesleukin, nivolumab
Patients will receive intra-tumoral (IT) NKTR-262 in 3-week treatment cycles. During the Phase 1 dose escalation portion of the trial, NKTR-262 will be combined with systemic administration of bempegaldesleukin. After determination of the recommended Phase 2 dose (RP2D) of NKTR-262, between 6 and 18 patients may be enrolled at the RP2D to further characterize the safety and tolerability profile of the combination of NKTR 262 plus bempegaldesleukin (doublet) or NKTR 262 plus bempegaldesleukin in combination with nivolumab (triplet) in Cohorts A and B, respectively. In the Phase 2 dose expansion portion, patients will be treated with doublet or triplet in the relapsed/refractory setting and earlier lines of therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Colorectal Cancer, Sarcoma
Melanoma Medical Oncology
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.